Rachel K. Bieu

Rachel K. Bieu

Auto-generated profile, based on publicly available information

Rachel K. Bieu

Robert J. Dole VA Medical Center

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
MSMakenna A. Snodgrass
Makenna A. Snodgrass
RBRachel K. Bieu
Rachel K. Bieu
RSRyan W. Schroeder
Ryan W. Schroeder
Objective: Anxiety disorders are the most prevalent psychiatric disorders experienced by individuals in the United States, and anxiety is often assessed with anxiety symptom inventories. At present, though, there are no anxiety symptom inventories that include symptom validity indices. The present study sought to develop a symptom validity index for the most commonly used anxiety symptom inventory in neuropsychological practice, the Beck Anxiety Inventory (BAI). Method: A sample of 244 veterans seeking outpatient neuropsychological assessments were included in the study. Participants were divided into valid and invalid groups based on external criterion symptom validity tests. The valid participants were then divided into clinical subgroups (Current Anxiety, Lifetime Anxiety, and No Anxiety). A validity index derived from the BAI total score was examined for the total sample and all subgroups. Results: A cutoff of ≥ 29 was identified when utilizing the Valid Full Sample, which resulted in a 0.91 specificity rate and 0.54 sensitivity rate. However, cutoffs had to be adjusted when applied to the clinical subgroups. The Valid Current Anxiety subgroup required the largest cutoff increase (i.e. ≥ 36), which resulted in a 0.91 specificity rate and a 0.42 sensitivity rate. Conclusions: This is the first published article to develop a symptom validity index for the BAI. To minimize false positive errors, a BAI total score of ≥ 36 is recommended.

22 November 2024 in The Clinical Neuropsychologist
Verified
Journal Article
Closed access
RSRobert D. Shura
Robert D. Shura
RSRyan W. Schroeder
Ryan W. Schroeder
AOAnna S. Ord
Anna S. Ord
RBRachel K. Bieu
Rachel K. Bieu
VOVictoria O'Connor
Victoria O'Connor
JRJared Rowland
Jared Rowland
Objective: The present study sought to cross validate the recently developed total score cut-off for the Beck Depression Inventory-II (BDI-II) and identify additional embedded symptom validity indices within this commonly used self-report depression measure. Methods: Study 1 included a research sample of 379 veterans with diagnostic subgroups of Current and Lifetime Depression and Current and Lifetime Posttraumatic Stress Disorder (PTSD). Study 2 included a clinical sample of 224 veterans with diagnostic subgroups of Current Depression, Lifetime Depression, and No Depression. Three embedded BDI-II symptom validity indices were examined in the total samples and subgroups: the BDI-II Symptom Severity Scale (total raw score), BDI-II Extreme Symptom Scale (summed frequency of extreme responses), and the BDI-II Rare Items Scale (summed frequency of rarely endorsed items). Validity indices from the Personality Assessment Inventory were utilized in both studies, with the Miller Forensic Assessment of Symptoms Test also used in Study 1. Results: In Study 1, BDI-II validity index cut-off scores had to be adjusted the highest for the Current Depression or Current PTSD subgroups. The cut-offs were associated with sensitivity rates ranging from 0.12 to 0.53 and specificity rates ranging from 0.90 to 0.96. In Study 2, cut-offs had to be adjusted, the highest for the Current Depression subgroup. Identified cut-offs had sensitivity rates ranging from 0.22 to 0.65 and specificity rates ranging from 0.89 to 0.95. Conclusions: This study supports the use of all three proposed BDI-II embedded symptom validity indices.

14 May 2025 in Military Psychology
Verified
Journal Article
Closed access
CHCharles A. Hayes
Charles A. Hayes
RBRachel K. Bieu
Rachel K. Bieu
RSRyan W. Schroeder
Ryan W. Schroeder
Unlike in efficacy trials, there can be notable variability in session frequency when PTSD treatment protocols, such a Prolonged Exposure (PE), are disseminated in clinical practice. The current study aimed to examine the impact of PE session frequency on treatment outcomes in a clinical Veteran sample. This study utilized retrospective data drawn from the Veterans Health Administration's Corporate Data Warehouse, a national data repository which includes Electronic Health Records. The extracted cohort of 648 Veterans was majority White-non-Hispanic and male [(Mage = 55.66 (14.08)]. All Veterans had a diagnosis of PTSD and completed in-person PE in outpatient Veterans Affairs behavioral health clinics between 2017 and 2018. The treatment outcome measure was the PTSD Checklist for DSM-5 (PCL-5). Linear multiple regression analyses did not find that session frequency predicted treatment outcome. Likewise, t-test results did not find differences in PCL-5 change scores based on session frequency. Effect sizes for pre- to post-treatment PCL-5 change scores ranged from d = 1.25 to 1.40. Overall, the current study suggests that PE may still be a useful intervention even when the treatment manual recommendation of weekly or twice weekly sessions cannot feasibly be conducted in clinical practice. Cross-validation is needed.